Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Lenalidomide and Dexamethasone for Acute Light Chain-Induced Renal Failure: Final Results of a Phase II Study

Heinz Ludwig, Univ. Prof. Dr., Elisabeth Rauch, Thomas Kuehr, MD, Adam Zdenek, MD, Adalbert Weissmann, MD, Hedwig Kasparu, MD, Eva-Maria Autzinger, MD, Daniel Heintel, MD, Richard Greil, MD, Wolfram Poenisch, MD, Niklas Zojer, MD, Ercan Müldür, MD

Blood (2014) 124 (21): 3484.

https://doi.org/10.1182/blood.V124.21.3484.3484

Published: 2014

Journal Articles

Bendamustine-bortezomib-dexamethasone is an active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma

Heinz Ludwig, Hedwig Kasparu, Clemens Leitgeb, Elisabeth Rauch, Werner Linkesch, Niklas Zojer, Richard Greil, Adelheid Seebacher, Ludek Pour, Adalbert Weißmann, Zdeněk Adam

Blood (2014) 123 (7): 985–991.

https://doi.org/10.1182/blood-2013-08-521468

Published: 2014

Journal Articles

Treatment with Bendamustine-Bortezomib-Dexamethasone (BBD) in Relapsed/Refractory Multiple Myeloma Shows Significant Activity and Is Well Tolerated

Heinz Ludwig, Hedwig Kasparu, Richard Greil, MD, Clemens Leitgeb, Ercan Müldür, Elisabeth Rauch, Niklas Zojer, Eva Maria Autzinger, Werner Linkesch, Thomas Kuhr, Ludek Pour, MD, PhD, Zdenek Adam

Blood (2012) 120 (21): 943.

https://doi.org/10.1182/blood.V120.21.943.943

Published: 2012

Journal Articles

Significant Activity of Lenalidomide-Dexamethasone in Multiple Myeloma (MM) Patients with Light Chain Induced Acute Renal Failure (LC-ARF)

Heinz Ludwig, Elisabeth Rauch, Thomas Kuhr, Adalbert Weissman, Daniel Heintel, Niklas Zojer, Hedwig Kasparu, Richard Greil, MD, Zdenek Adam

Blood (2012) 120 (21): 4031.

https://doi.org/10.1182/blood.V120.21.4031.4031

Published: 2012

Journal Articles

Bortezomib-Bendamustine-Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (MM) Shows Marked Efficacy and Is Well Tolerated, but Assessment of PNP Symptoms Shows Significant Discrepancies Between Patients and Physicians

Heinz Ludwig, MD, Hedwig Kasparu, Werner Linkesch, MD, Josef Thaler, Richard Greil, MD, Clemens Leitgeb, Daniel Heintel, Elisabeth Rauch, Niklas Zojer, Ludek Pour, Adelheid Seebacher, Zdenek Adam

Blood (2011) 118 (21): 2928.

https://doi.org/10.1182/blood.V118.21.2928.2928

Published: 2011

Journal Articles

Response: Significant influence of LCT-13910C>T on transplantation outcomes in acute myeloid leukemia patients receiving transplantations from HLA-identical sibling donors

Hanns Hauser, Otto Zach, Otto Krieger, Hedwig Kasparu, Josef Koenig, Michael Girschikofsky, Dieter Lutz

Blood (2010) 115 (17): 3645–3646.

https://doi.org/10.1182/blood-2010-02-268367

Published: 2010

Journal Articles

Double Transplantation with Melphalan (200 mg/m 2 ) Compared with Triple Transplantation with Intermediate Dose Melphalan (100 mg/m 2 ) in Patients with Multiple Myeloma

Heinz Ludwig, MD, Ivan Spicka, MD, Werner Linkesch, MD, Richard Greil, Hedwig Kasparu, MD, Eberhard Gunsilius, MD, Josef Thaler, MD, Johannes Drach, MD, Ingrid Kuhn, MD, Adalbert Weiβmann, MD, Axel Hinke, PhD

Blood (2008) 112 (11): 3317.

https://doi.org/10.1182/blood.V112.11.3317.3317

Published: 2008

Journal Articles

A single nucleotide polymorphism at chromosome 2q21.3 (LCT −13910C>T) associates with clinical outcome after allogeneic hematopoietic stem cell transplantation

Hanns Hauser, Otto Zach, Otto Krieger, Hedwig Kasparu, Josef Koenig, Michael Girschikofsky, Rainer Oberbauer, Dieter Lutz

Blood (2008) 112 (5): 2156–2159.

https://doi.org/10.1182/blood-2008-02-139766

Published: 2008

Includes: Supplemental data

Journal Articles

Prospective, Randomized Comparison between Double Transplantation (T) with Melphalan (200 mg/m 2 ) and Triple T with Intermediate Dose Melphalan (100 mg/m 2 ) in Patients with Multiple Myeloma (An Interim Analysis).

Heinz Ludwig, MD, Werner Linkesch, MD, Hedwig Kasparu, MD, Otto Krieger, MD, Ivan Spicka, MD, Gunther Gastl, MD, Richard Greil, MD, Johannes Drach, MD, Josef Thaler, MD, Ingrid Kuhn, Niklas Zojer, MD, Axel Hinke, PhD

Blood (2006) 108 (11): 3083.

https://doi.org/10.1182/blood.V108.11.3083.3083

Published: 2006

NARROW

Lenalidomide and Dexamethasone for Acute Light Chain-Induced Renal Failure: Final Results of a Phase II Study

Bendamustine-bortezomib-dexamethasone is an active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma

Treatment with Bendamustine-Bortezomib-Dexamethasone (BBD) in Relapsed/Refractory Multiple Myeloma Shows Significant Activity and Is Well Tolerated

Significant Activity of Lenalidomide-Dexamethasone in Multiple Myeloma (MM) Patients with Light Chain Induced Acute Renal Failure (LC-ARF)

Bortezomib-Bendamustine-Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (MM) Shows Marked Efficacy and Is Well Tolerated, but Assessment of PNP Symptoms Shows Significant Discrepancies Between Patients and Physicians

Response: Significant influence of LCT-13910C>T on transplantation outcomes in acute myeloid leukemia patients receiving transplantations from HLA-identical sibling donors

Double Transplantation with Melphalan (200 mg/m 2 ) Compared with Triple Transplantation with Intermediate Dose Melphalan (100 mg/m 2 ) in Patients with Multiple Myeloma

A single nucleotide polymorphism at chromosome 2q21.3 (LCT −13910C>T) associates with clinical outcome after allogeneic hematopoietic stem cell transplantation

Prospective, Randomized Comparison between Double Transplantation (T) with Melphalan (200 mg/m 2 ) and Triple T with Intermediate Dose Melphalan (100 mg/m 2 ) in Patients with Multiple Myeloma (An Interim Analysis).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only